Reports: Interim report Q3 2024

Press release from Companies: The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share

Press release from Companies: Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Økonomisk Ugebrev Investor Conference

Press release from Companies: Curasight announces international patent application for uTREAT® to broaden IP protection

Press release from Companies: Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025

Press release from Companies: Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025

Press release from Companies: Curasight to present at Dansk Aktionærforening InvestorDagen

Press release from Companies: Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer

Press release from Companies: Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3

Press release from Companies: Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3

Press release from Companies: Curasight A/S rights issue heavily oversubscribed

Press release from Companies: Commencement of subscription period in Curasight’s preferential rights issue